| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
While more than 50% of neuroblastoma patients with stage 4 disease have experienced tumor relapses, patients with stage 4S pattern of disease (characterized by metastases limited to liver, skin, and bone marrow) have experienced spontaneous tumor regression. The molecular mechanism responsible for the difference between stage 4 and 4S patinets remains elusive. In the present study, we have focused on Evi5, which was isolated from t(1;10)(p22;q21) in non-tumor cells from a stage 4S patient, and examined its role in the progression of neuroblastoma. We have identified a novel Evi5 isoform (Evi5-NB) that is specifically expressed in neuroblastoma, and revealed that the sphere, colony and xenograft formation of neuroblastoma cells were diminished upon Evi5 knockdown.
|
